| 胰高血糖素样肽1影响动脉粥样硬化的研究进展 |
| |
| 引用本文： | 李波,陈韵岱.胰高血糖素样肽1影响动脉粥样硬化的研究进展[J].中国动脉硬化杂志,2017,25(4):427-432. |
| |
| 作者姓名： | 李波 陈韵岱 |
| |
| 作者单位： | 中国人民解放军总医院心血管内科, 北京市 100853,中国人民解放军总医院心血管内科, 北京市 100853 |
| |
| 摘 要： | 胰高血糖素样肽1(GLP-1)是一种新型治疗2型糖尿病肠促胰液素,它可以在进食后血糖升高而刺激肠道分泌进而控制血糖。越来越多的研究表明,GLP-1可直接作用于心血管系统,例如可以影响内皮功能、炎症反应、血压、血脂代谢等。本文将对GLP-1类药物包括GLP-1类似物和二肽激肽酶4抑制剂影响动脉粥样硬化以及其潜在的机制进行综述。
|
| 关 键 词： | 胰高血糖素样肽1 胰高血糖素样肽1受体激动剂 二肽激肽酶4抑制剂 动脉粥样硬化 |
| 收稿时间： | 2016/6/3 0:00:00 |
| 修稿时间： | 2016/11/17 0:00:00 |
Review of glucagon-like peptide-1 in the management of atherosclerosis |
| |
| LI Bo and CHEN Yun-Dai.Review of glucagon-like peptide-1 in the management of atherosclerosis[J].Chinese Journal of Arteriosclerosis,2017,25(4):427-432. |
| |
| Authors: | LI Bo and CHEN Yun-Dai |
| |
| Institution: | Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China and Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China |
| |
| Abstract: | Glucagon-like peptide-1 (GLP-1) is an incretin hormone whose glucose-dependent insulinotropic actions have been regulated as a novel therapy for glycemic control in diabetes. Emerging evidence indicates that GLP-1 exerts direct effects on specific aspects of cardiovascular disease, such as endothelial dysfunction, inflammation, blood pressure and lipid metabolism. This review will focus on the effects of incretin therapies, including GLP-1 analogs and dipeptidyl peptidase (DPP)-4 inhibitors, on the atherosclerosis disease, and will discuss the potential mechanisms underlying these effects. |
| |
| Keywords: | Glucagon-like peptide-1 Glucagon-like peptide 1 analogue Dipeptidyl peptidase-4 inhibitor Atherosclerosis |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国动脉硬化杂志》浏览原始摘要信息 |
| 点击此处可从《中国动脉硬化杂志》下载免费的PDF全文 |
|
